• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Live Nation Entertainment, Groupon And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

    4/16/24 6:53:41 AM ET
    $CLNE
    $GRPN
    $INO
    $LII
    Natural Gas Distribution
    Utilities
    Advertising
    Consumer Discretionary
    Get the next $CLNE alert in real time by email

    U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Tuesday.

    Shares of Live Nation Entertainment, Inc. (NYSE:LYV) fell sharply in today’s pre-market trading following a report indicating the Justice Department will file an antitrust lawsuit against the company.

    Live Nation Entertainment shares dipped 7.8% to $92.02 in pre-market trading.

    Here are some big stocks recording losses in today’s pre-market trading session.

    • Inovio Pharmaceuticals, Inc. (NASDAQ:INO) shares dipped 24.3% to $8.32 in pre-market trading. INOVIO priced its $36 million underwritten offering of 2,536,258 common stock at $7.693 per share.
    • Groupon, Inc. (NASDAQ:GRPN) shares declined 8.9% to $9.11 in pre-market trading. Groupon said Italian tax authorities have placed a lien on Groupon S.r.l.'s bank account, which currently restricts outgoing payments from that account.
    • Lyell Immunopharma Inc (NASDAQ:LYEL) shares fell 7.1% to $2.23 in pre-market trading after dipping 20% on Monday.
    • ArcelorMittal SA (NYSE:MT) shares fell 6% to $25.33 in pre-market trading after Deutsche Bank downgraded the stock from Buy to Hold.
    • Tevogen Bio Holdings Inc (NASDAQ:TVGN) shares declined 6% to $2.21 in pre-market trading following a 4% decline on Monday.
    • Lennox International Inc (NYSE:LII) shares fell 5.8% to $434.82 in pre-market trading. Lennox is expected to report first quarter 2024 financial results before the opening bell on April 24, 2024.
    • Clean Energy Fuels Corp (NASDAQ:CLNE) shares declined 5.6% to $2.20 in pre-market trading after falling around 5% on Monday.

     

    Now Read This: Johnson & Johnson Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

    Don’t forget to check out our premarket coverage here

    Get the next $CLNE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLNE
    $GRPN
    $INO
    $LII

    CompanyDatePrice TargetRatingAnalyst
    Live Nation Entertainment Inc.
    $LYV
    3/30/2026$190.00Mkt Outperform
    Citizens
    Arcelor Mittal NY Registry Shares NEW
    $MT
    3/25/2026Sector Weight
    KeyBanc Capital Markets
    Lyell Immunopharma Inc.
    $LYEL
    3/9/2026$34.00Mkt Outperform
    Citizens
    Arcelor Mittal NY Registry Shares NEW
    $MT
    3/9/2026Overweight → Underweight
    Analyst
    Tevogen Bio Holdings Inc.
    $TVGN
    3/4/2026Buy → Hold
    D. Boral Capital
    Live Nation Entertainment Inc.
    $LYV
    2/27/2026$193.00Neutral → Buy
    Rothschild & Co Redburn
    Live Nation Entertainment Inc.
    $LYV
    2/25/2026$204.00Overweight
    Wells Fargo
    Arcelor Mittal NY Registry Shares NEW
    $MT
    2/11/2026Hold → Buy
    Jefferies
    More analyst ratings

    $CLNE
    $GRPN
    $INO
    $LII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Arch Venture Partners Ix, Llc bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    3/9/26 4:36:20 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Arch Venture Fund Xiii, L.P. bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    3/9/26 4:34:54 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Brawley Otis W bought $19,958 worth of shares (35,640 units at $0.56) (SEC Form 4)

    4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)

    4/2/25 3:46:01 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNE
    $GRPN
    $INO
    $LII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Capo Brian

    4 - Live Nation Entertainment, Inc. (0001335258) (Issuer)

    4/2/26 4:22:48 PM ET
    $LYV
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 4 filed by Sumner Michael John

    4 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Issuer)

    4/1/26 5:05:12 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Shah Amit

    3 - Groupon, Inc. (0001490281) (Issuer)

    4/1/26 5:02:55 PM ET
    $GRPN
    Advertising
    Consumer Discretionary

    $CLNE
    $GRPN
    $INO
    $LII
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ArcelorMittal has published a convening notice for its Annual General Meeting and Extraordinary General Meeting of shareholders to be held on 5 May 2026

    3 April 2026, 8.00am CET ArcelorMittal (the ‘Company') announces the publication of the convening notice for its Annual General Meeting and Extraordinary General Meeting of shareholders (the "General Meetings"), which will be held on 5 May 2026 at 11:00 a.m. CET at the Company's registered office, 24-26, boulevard d'Avranches, L-1160 Luxembourg, Grand-Duchy of Luxembourg. The ArcelorMittal shareholders entitled to vote at the General Meetings will be those who are shareholders on the record date of 21 April 2026 at midnight (24:00 hours CET) (the "Record Date"). The Annual General Meeting's agenda includes the re-election of Mr. Lakshmi Niwas Mittal, Mr. Aditya Mittal, Mr. Michel Wurth an

    4/3/26 2:00:00 AM ET
    $MT
    Steel/Iron Ore
    Industrials

    INOVIO Announces Pricing of $17.5 Million Public Offering

    PLYMOUTH MEETING, Pa., April 2, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock and accompanying Series A warrants to purchase up to 12,500,000 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price of $1.40 per share of common stock and Series B warrants to purchase up to 12,500,000 shares of its common stock (or pre-funded warrants in lieu thereof) at an exercise price

    4/2/26 8:55:00 AM ET
    $INO
    Medical/Dental Instruments
    Health Care

    INOVIO Announces Proposed Public Offering

    PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying Series A warrants and Series B warrants to purchase shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof), in an underwritten public offering. All of the securities in the proposed offering will be sold by INOVIO. INOVIO intends to grant the underwriter a 30-day option to purchase additional s

    4/1/26 8:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $CLNE
    $GRPN
    $INO
    $LII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citizens initiated coverage on Live Nation with a new price target

    Citizens initiated coverage of Live Nation with a rating of Mkt Outperform and set a new price target of $190.00

    3/30/26 8:19:42 AM ET
    $LYV
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    KeyBanc Capital Markets resumed coverage on ArcelorMittal

    KeyBanc Capital Markets resumed coverage of ArcelorMittal with a rating of Sector Weight

    3/25/26 8:29:02 AM ET
    $MT
    Steel/Iron Ore
    Industrials

    Citizens initiated coverage on Lyell Immunopharma with a new price target

    Citizens initiated coverage of Lyell Immunopharma with a rating of Mkt Outperform and set a new price target of $34.00

    3/9/26 9:07:38 AM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLNE
    $GRPN
    $INO
    $LII
    SEC Filings

    View All

    SEC Form S-3 filed by Lyell Immunopharma Inc.

    S-3 - Lyell Immunopharma, Inc. (0001806952) (Filer)

    4/3/26 4:23:10 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Arcelor Mittal NY Registry Shares NEW

    6-K - ArcelorMittal (0001243429) (Filer)

    4/3/26 11:55:47 AM ET
    $MT
    Steel/Iron Ore
    Industrials

    SEC Form 424B5 filed by Inovio Pharmaceuticals Inc.

    424B5 - INOVIO PHARMACEUTICALS, INC. (0001055726) (Filer)

    4/2/26 4:56:53 PM ET
    $INO
    Medical/Dental Instruments
    Health Care

    $CLNE
    $GRPN
    $INO
    $LII
    Leadership Updates

    Live Leadership Updates

    View All

    Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results

    Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) evaluating ronde-cel is ongoingPhase 1 trial is ongoing for LYL273, an enhanced GCC-targeted CAR T-cell candidate for metastatic colorectal cancer; seven new patients treated without dose-limiting toxicity and including dose escalation to Dose Level 3Smital Shah was appointed Chief Financial and Business Officer in March 2026Second $50 million tranche of $100 million equity private placement closed in March 2026 after achievement of clinical milestone for ronde-celCash of approximate

    3/12/26 4:05:00 PM ET
    $LYEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform

    WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN) today issued a statement from Founder and CEO Dr. Ryan Saadi regarding the company's progress in developing TVGN 489 for Long COVID, timed with International Long COVID Awareness Month. Following the appointment of a new leadership team on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to move TVGN 489 into its next clinical phase. The company is currently evaluating the acquisition of Sciometrix and its Clinicus platform to provide real-world monitoring for Long COVID patients. Tevogen continues to prioritize the development of TVGN 489,

    3/11/26 3:15:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Groupon Launches Board-Level Artificial Intelligence Committee and Appoints Amit Shah to Board of Directors

    Technology executive and AI entrepreneur to chair new committee as Company positions marketplace for the era of agentic commerceChicago, Illinois--(Newsfile Corp. - March 10, 2026) - Groupon, Inc. (NASDAQ:GRPN) today announced the appointment of Amit Shah to its Board of Directors, effective March 10, 2026, and the formation of a dedicated Artificial Intelligence Committee of the Board. Shah, a seasoned technology executive and AI entrepreneur, will serve as the Committee's inaugural Chair.With this action, Groupon becomes one of the first publicly traded consumer marketplaces to establish a board-level committee dedicated to artificial intelligence. The formation of the Committee reflects t

    3/10/26 4:15:00 PM ET
    $APRN
    $FLWS
    $GRPN
    Catalog/Specialty Distribution
    Consumer Discretionary
    Other Specialty Stores
    Advertising

    $CLNE
    $GRPN
    $INO
    $LII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Groupon Inc.

    SC 13G - Groupon, Inc. (0001490281) (Subject)

    12/13/24 10:39:00 AM ET
    $GRPN
    Advertising
    Consumer Discretionary

    SEC Form SC 13G filed by Groupon Inc.

    SC 13G - Groupon, Inc. (0001490281) (Subject)

    12/6/24 2:12:18 PM ET
    $GRPN
    Advertising
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Groupon Inc.

    SC 13G/A - Groupon, Inc. (0001490281) (Subject)

    11/14/24 6:51:01 PM ET
    $GRPN
    Advertising
    Consumer Discretionary

    $CLNE
    $GRPN
    $INO
    $LII
    Financials

    Live finance-specific insights

    View All

    Lennox Declares Quarterly Dividend

    DALLAS, March 20, 2026 /PRNewswire/ -- The Lennox board of directors (NYSE:LII) approved a quarterly cash dividend of $1.30 per share of common stock, payable April15, 2026, to stockholders of record as of March 31, 2026.About Lennox: Lennox (NYSE: LII ) is a leader in energy-efficient climate-control solutions. We are committed to sustainability and creating comfortable, healthier environments for residential and commercial customers. Our innovative portfolio includes cooling, heating, indoor air quality, and refrigeration systems, along with a comprehensive range of HVAC parts, supplies, and services that support the full lifecycle of customer needs. Additional information is available at 

    3/20/26 10:19:00 AM ET
    $LII
    Industrial Machinery/Components
    Industrials

    Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization

    Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes cash-flow positive.Approximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen's lead investor, directors and named executive officers.Company prioritizing long-term stock-based incentive program aligned with company milestones.Board of Directors continues to evaluate the potential declaration of a one-time special cash dividend to shareholders.Company continues to evaluate acquisitions that could generate

    3/13/26 2:45:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

    Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U.S. Food and Drug Administration (FDA); target Prescription Drug User Fee Act (PDUFA) date October 30, 2026 INO-3107 immunological and long-term clinical and safety data published in Nature Communications and The Laryngoscope Advanced promising next-generation DNA medicine technology:Phase 1 proof-of-concept trial of DNA-encoded Monoclonal Antibodies (DMAbs) published in Nature MedicinePromising preclinical data on novel DNA-encoded protein (DPROT) technology presented at the World Federation of

    3/12/26 4:05:00 PM ET
    $INO
    Medical/Dental Instruments
    Health Care